September 30, 2025/
Pharmacovigilance (PV) is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem. In simpler terms, it is...
ALVigiLance is a dedicated pharmacovigilance platform designed to support the healthcare team in ensuring safer medication use. Our mission is simple yet vital: to provide trusted insights, practical tools, and up-to-date resources that empower healthcare professionals to identify, prevent, and manage adverse drug reactions (ADRs).
Simplified, practical guides on drug safety and monitoring.
Real-world examples to strengthen your clinical decision-making.
Summaries of global drug warnings and regulatory actions.
Strategies for adverse event reporting, risk management, and patient counseling.
To create a proactive community of healthcare providers who champion medication safety and improve patient outcomes through shared knowledge and vigilance.
Medication safety is everyone’s responsibility. Explore, learn, and engage with ALVigiLance — because together, we can reduce risks and save lives.
Pharmacovigilance (PV) is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem. In simpler terms, it is...
This document communicates important safety updates for three different categories of products, focusing on new aspects of known risks. Extracts from PRAC – July 2025.
Ciltabtagene autoleucel (Carvykti), Immune-mediated enterocolitis. Brodalumab, Pyoderma gangrenosum. Enzalutamide & Digoxin, Laboratory test interference leading to falsely elevated digoxin levels. Vortioxetine, Hallucinations, not related to serotonin syndrome
